ADB-BUTINACA-d9 (CRM) is intended for use as an internal standard for the quantification of ADB-BUTINACA by GC- or LC-MS. ADB-BUTINACA is categorized as a synthetic cannabinoid.[1] ADB-BUTINACA is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.
References:
[1].Sparkes, E., Cairns, E.A., Kevin, R.C., et al.Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICARSC Med. Chem.13(2)156-174(2021).
















